Silkim Pharma Overview
Silkim Pharma has developed a novel, protected platform of drugs for proven treatments of multiple indications. The company's platform is the result of extensive investigation of animal models of human diseases. Members of the platform act as potent anti-inflammatory agents, strong iron-chelating agents, and antibiotic agents. These modes of action jointly assist in treating the causes and/or symptoms of multiple indications.
Latest News
growth-positive
Silkim Pharma's New Drug Against Coronavirus Receives Response from FDA in Record Time!! - JLM-BioCity
Silkim Pharma has filed a pre-Investigational New Drug (PIND) meeting request with the FDA for its drug candidate CORONZOT in the treatment of COVID-19 patients. The FDA responded positively and provided guidance on the planned clinical study. Silkim Pharma plans to submit an IND application for CORONZOT. The drug addresses the exaggerated immune system reaction caused by the coronavirus. It employs a novel mechanism based on sequestration of labile iron and introduces an ion of gallium or zinc. Silkim Pharma is a pharmaceutical company established in 2017 and is focused on developing drugs for multiple indications.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Mature |
| Rounds | 0 |
| Investors | 0 |
Team Members
2
Employees: 1-10
Web & Social Links
| Website | www.silkim.com/ |
Locations
Ranana, Israel
Photos & Videos
No files yet
